News & Updates

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.

Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.

Breast cancer survivors who are at least 50 years of age appear to do well with less frequent mammographic surveillance, with survival outcomes being no worse than with annual mammograms, according to data from the phase III Mammo-50 trial.

For postmenopausal women with genomically defined low-risk stage I breast cancer who have been initiated on endocrine therapy immediately after breast-conserving surgery, the risk of recurrence is low despite the omission of radiation therapy, as shown in the IDEA* trial.

The addition of carfilzomib to lenalidomide and dexamethasone (KRd) improved outcomes in individuals with newly diagnosed fit or intermediate-fit multiple myeloma who are transplant ineligible (NTE NDMM) as opposed to Rd only in the phase III EMN20 trial.

The addition of capivasertib (C) to fulvestrant (F) results in better health-related quality of life (HRQoL), except for diarrhoea, in patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer when compared to placebo plus F, according to the phase III CAPItello-291 study presented at SABCS 2023.

Body mass index (BMI) has some bearing on the efficacy of different adjuvant chemotherapy schedules in patients with early breast cancer, suggest the results of the GIM2 study, which were presented at the recent SABCS 2023. Additionally, dose-dense (DD) chemotherapy appears to be the better treatment strategy regardless of a patient’s BMI.